Back to News
Market Impact: 0.25
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
Source: GlobeNewswire
Healthcare & BiotechRegulation & LegislationProduct Launches
A regulatory filing seeks approval for a biomarker-directed, all-oral treatment for patients with MET-overexpressing or MET-amplified tumors whose disease progressed following EGFR-TKI therapy. If approved, the treatment could provide an additional targeted option for this post-progression cancer population.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Anthropic warns AI may pose 'existential risks to humanity' in IPO filing: Reuters
- Fake Obesity Jabs And Experimental Drugs Cloud India's Weight-Loss Boom
- Exclusive-Anthropic’s IPO prospectus shows sweeping AI vision, surging costs
- Oil prices rise for second session on continued Middle East supply concern
- AMD will acquire Fei-Fei Li’s World Labs for $8.2 billion
- OpenAI scraps release of new model on safety concerns- WSJ